Quick Answer
Allarity Therapeutics, Inc. reported Stockholders Equity of $9.83 million for the year ending 2025.
- Allarity Therapeutics, Inc. showed a decrease of -16.8% in Stockholders Equity from 2024 to 2025.
- This data is from Allarity Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $22.29 million | Q2 2020: $22.75 million | Q3 2020: $24.66 million | Q1 2021: $23.47 million | Q2 2021: $28.82 million | Q3 2021: $29.66 million | Q1 2022: $14.73 million | Q2 2022: $7.97 million | Q3 2022: $1.45 million | Q1 2023: -$3.10 million | Q2 2023: -$723.0 thousand | Q3 2023: -$3.38 million | Q1 2024: -$6.47 million | Q2 2024: $19.84 million | Q3 2024: $12.96 million | Q1 2025: $18.67 million | Q2 2025: $12.17 million | Q3 2025: $12.01 million.
- Over the full 7 years of available data (2019 to 2025), Allarity Therapeutics, Inc.'s Stockholders Equity has declined by 50.9%.
- Historical annual values: Fiscal year 2025: $9.83 million | Fiscal year 2024: $11.81 million | Fiscal year 2023: -$2.75 million | Fiscal year 2022: -$113.0 thousand | Fiscal year 2021: $18.15 million | Fiscal year 2020: $24.44 million | Fiscal year 2019: $20.04 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: